Cost of cancer therapies, both new and old, have risen considerably during the past decade. Take pegaspargase, first approved for use in Europe and USA in 1994 for the treatment of acute lymphocytic lymphoma. During the intervening 22 years, pegaspargase has been transferred between three companies and its price in the Unites States has increased from around $1500 to over $15 000 per dose (Figure 1) [1, 2].

Figure 1.
Cost of pegasparaginase compared to US healthcare inflation. CPI-M; consumer price index, medical care.
View largeDownload slide

Cost of pegasparaginase compared to US healthcare inflation. CPI-M; consumer price index, medical care.

Figure 1.
Cost of pegasparaginase compared to US healthcare inflation. CPI-M; consumer price index, medical care.
View largeDownload slide

Cost of pegasparaginase compared to US healthcare inflation. CPI-M; consumer price index, medical care.

...

Rising cancer treatment costs strain insurers and public healthcare systems. In addition,...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.